News Accolade, Inc.

Equities

ACCD

US00437E1029

Real-time Estimate Cboe BZX Other stock markets 02:41:01 2024-05-15 pm EDT			5-day change	1st Jan Change
7.4 ^USD	+0.54%		+4.14%	-38.26%

Apr. 30	Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating	MT
Apr. 26	Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating	Apr. 30	MT
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating	Apr. 26	MT
Accolade : Investor Presentation	Apr. 25	PU
Transcript : Accolade, Inc., Q4 2024 Earnings Call, Apr 25, 2024	Apr. 25
Accolade, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended February 29, 2024	Apr. 25	CI
Accolade: Fiscal Q4 Earnings Snapshot	Apr. 25	AQ
Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024	Apr. 25	GL
Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating	Apr. 22	MT
Accolade to Announce Fiscal Fourth Quarter 2024 Financial Results	Apr. 03	AQ
Accolade Wins 2024 Artificial Intelligence Excellence Award	Mar. 20	PR
Accolade Promotes Kelsi McDonald Harris to Chief People Officer	Mar. 19	PR
Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President	Mar. 19	CI
Transcript : Accolade, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	Mar. 13
Accolade To Present at Upcoming Investor Conferences	Feb. 28	AQ
Leerink Partners Initiates Accolade at Outperform Rating With $16 Price Target	Feb. 26	MT
Accolade Welcomes Kindbody to Trusted Partner Ecosystem	Jan. 23	PR
Accolade Insider Sold Shares Worth $1,554,504, According to a Recent SEC Filing	Jan. 12	MT
Transcript : Accolade, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
Accolade Shares Surge After Raymond James Upgrade, Fiscal Q3 Results	Jan. 09	MT
Raymond James Adjusts Accolade's Price Target to $16 From $12, Keeps Outperform Rating	Jan. 09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Accolade, Inc.

Equities

ACCD

US00437E1029

Summary

Filters